Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Richard J. Simensen is active.

Publication


Featured researches published by Richard J. Simensen.


American Journal of Medical Genetics | 1998

Autism and maternally derived aberrations of chromosome 15q

Richard J. Schroer; Mary C. Phelan; Ron C. Michaelis; Eric Crawford; Steven A. Skinner; Michael L. Cuccaro; Richard J. Simensen; Janet Bishop; Cindy Skinner; Don Fender; Roger E. Stevenson

Of the chronic mental disabilities of childhood, autism is causally least well understood. The former view that autism was rooted in exposure to humorless and perfectionistic parenting has given way to the notion that genetic influences are dominant underlying factors. Still, identification of specific heritable factors has been slow with causes identified in only a few cases in unselected series. A broad search for genetic and environmental influences that cause or predispose to autism is the major thrust of the South Carolina Autism Project. Among the first 100 cases enrolled in the project, abnormalities of chromosome 15 have emerged as the single most common cause. The four abnormalities identified include deletions and duplications of proximal 15q. Other chromosome aberrations seen in single cases include a balanced 13;16 translocation, a pericentric inversion 12, a deletion of 20p, and a ring 7. Candidate genes involved in the 15q region affected by duplication and deletion include the ubiquitin-protein ligase (UBE3A) gene responsible for Angelman syndrome and genes for three GABA(A) receptor subunits. In all cases, the deletions or duplications occurred on the chromosome inherited from the mother.


American Journal of Human Genetics | 2005

Allan-Herndon-Dudley Syndrome and the Monocarboxylate Transporter 8 (MCT8) Gene

Charles E. Schwartz; Melanie M. May; Nancy J. Carpenter; R. Curtis Rogers; Judith Martin; Martin G. Bialer; Jewell C. Ward; Javier Sanabria; Silvana Marsa; James A. Lewis; Roberto J. Echeverri; Herbert A. Lubs; Kytja K. S. Voeller; Richard J. Simensen; Roger E. Stevenson

Allan-Herndon-Dudley syndrome was among the first of the X-linked mental retardation syndromes to be described (in 1944) and among the first to be regionally mapped on the X chromosome (in 1990). Six large families with the syndrome have been identified, and linkage studies have placed the gene locus in Xq13.2. Mutations in the monocarboxylate transporter 8 gene (MCT8) have been found in each of the six families. One essential function of the protein encoded by this gene appears to be the transport of triiodothyronine into neurons. Abnormal transporter function is reflected in elevated free triiodothyronine and lowered free thyroxine levels in the blood. Infancy and childhood in the Allan-Herndon-Dudley syndrome are marked by hypotonia, weakness, reduced muscle mass, and delay of developmental milestones. Facial manifestations are not distinctive, but the face tends to be elongated with bifrontal narrowing, and the ears are often simply formed or cupped. Some patients have myopathic facies. Generalized weakness is manifested by excessive drooling, forward positioning of the head and neck, failure to ambulate independently, or ataxia in those who do ambulate. Speech is dysarthric or absent altogether. Hypotonia gives way in adult life to spasticity. The hands exhibit dystonic and athetoid posturing and fisting. Cognitive development is severely impaired. No major malformations occur, intrauterine growth is not impaired, and head circumference and genital development are usually normal. Behavior tends to be passive, with little evidence of aggressive or disruptive behavior. Although clinical signs of thyroid dysfunction are usually absent in affected males, the disturbances in blood levels of thyroid hormones suggest the possibility of systematic detection through screening of high-risk populations.


Nature Genetics | 2007

Mutations in UPF3B , a member of the nonsense-mediated mRNA decay complex, cause syndromic and nonsyndromic mental retardation

Patrick Tarpey; F. Lucy Raymond; Lam Son Nguyen; Jayson Rodriguez; Anna Hackett; Lucianne Vandeleur; Raffaella Smith; Cheryl Shoubridge; Sarah Edkins; Claire Stevens; Sarah O'Meara; Calli Tofts; Syd Barthorpe; Gemma Buck; Jennifer Cole; Kelly Halliday; Katy Hills; David Jones; Tatiana Mironenko; Janet Perry; Jennifer Varian; Sofie West; Sara Widaa; J Teague; Ed Dicks; Adam Butler; Andrew Menzies; David C. Richardson; Andrew M. Jenkinson; Rebecca Shepherd

Nonsense-mediated mRNA decay (NMD) is of universal biological significance. It has emerged as an important global RNA, DNA and translation regulatory pathway. By systematically sequencing 737 genes (annotated in the Vertebrate Genome Annotation database) on the human X chromosome in 250 families with X-linked mental retardation, we identified mutations in the UPF3 regulator of nonsense transcripts homolog B (yeast) (UPF3B) leading to protein truncations in three families: two with the Lujan-Fryns phenotype and one with the FG phenotype. We also identified a missense mutation in another family with nonsyndromic mental retardation. Three mutations lead to the introduction of a premature termination codon and subsequent NMD of mutant UPF3B mRNA. Protein blot analysis using lymphoblastoid cell lines from affected individuals showed an absence of the UPF3B protein in two families. The UPF3B protein is an important component of the NMD surveillance machinery. Our results directly implicate abnormalities of NMD in human disease and suggest at least partial redundancy of NMD pathways.


The Lancet | 1997

Autism and macrocephaly

Roger E. Stevenson; Richard J. Schroer; Cindy Skinner; Don Fender; Richard J. Simensen

Aberrations of brain growth are often associated with impairments in central-nervous-system function. Severe undergrowth of the brain carries a high risk of impaired cognitive function. Brain overgrowth may be associated with cognitive impairment, but in general has a less ominous prognosis than undergrowth. Several external measurements have been used to assess brain size. Occipitofrontal head circumference is the measure most widely accepted in clinical practice. Microcephaly (head circumference 2 SD or more below the mean) is correlated with clinically significant undergrowth of the brain, and macrocephaly (head circumference 2 SD or more above the mean) with overgrowth of the brain. Brain size may also be determined indirectly with cranial imaging techniques or by direct measurement at necropsy. Macrocephaly has been reported in retrospective and prospective surveys of individuals with autism. Bailey and colleagues reported macrocephaly (head circumference >97th centile) in 42% (nine of 19) twins with autism under 16 years of age. They also found macrocephaly in 37% of singletons with autism under 16 years of age. In a retrospective review, Davidovitch et al found macrocephaly in 18·2% (27 of 148) individuals with autism. Increased height and weight frequently accompanied the macrocephaly. Lainhart and colleagues found 14% of 91 individuals (60 children and 31 adults) with autism to have head circumferences above the 97th percentile. Excess brain weights have been noted THE LANCET


Journal of Medical Genetics | 2007

The original Lujan syndrome family has a novel missense mutation (p.N1007S) in the MED12 gene

Charles E. Schwartz; Patrick Tarpey; Herbert A. Lubs; Alain Verloes; Melanie M. May; Hiba Risheg; Michael J. Friez; P. Andrew Futreal; Sarah Edkins; Jon Teague; Sylvain Briault; Cindy Skinner; Astrid Bauer-Carlin; Richard J. Simensen; Sumy M Joseph; Julie R. Jones; Jozef Gecz; Michael R. Stratton; F. Lucy Raymond; Roger E. Stevenson

A novel missense mutation in the mediator of RNA polymerase II transcription subunit 12 (MED12) gene has been found in the original family with Lujan syndrome and in a second family (K9359) that was initially considered to have Opitz–Kaveggia (FG) syndrome. A different missense mutation in the MED12 gene has been reported previously in the original family with FG syndrome and in five other families with compatible clinical findings. Neither sequence alteration has been found in over 1400 control X chromosomes. Lujan (Lujan–Fryns) syndrome is characterised by tall stature with asthenic habitus, macrocephaly, a tall narrow face, maxillary hypoplasia, a high narrow palate with dental crowding, a small or receding chin, long hands with hyperextensible digits, hypernasal speech, hypotonia, mild-to-moderate mental retardation, behavioural aberrations and dysgenesis of the corpus callosum. Although Lujan syndrome has not been previously considered to be in the differential diagnosis of FG syndrome, there are some overlapping clinical manifestations. Specifically, these are dysgenesis of the corpus callosum, macrocephaly/relative macrocephaly, a tall forehead, hypotonia, mental retardation and behavioural disturbances. Thus, it seems that these two X-linked mental retardation syndromes are allelic, with mutations in the MED12 gene.


Journal of Autism and Developmental Disorders | 2002

Longitudinal Changes in Cognitive and Adaptive Behavior Scores in Children and Adolescents with the Fragile X Mutation or Autism.

Gene S. Fisch; Richard J. Simensen; Richard J. Schroer

Studies of the relationship between the fragile X (FRAXA) mutation and autism have been controversial. Although there are differences between the two populations, individuals with FRAXA and autism exhibit remarkably similar aberrant behavior patterns. We examined comparably aged children and adolescents with FRAXA or autism to determine whether longitudinal changes in cognitive ability and adaptive behavior were similar in the two groups. We found decreases in IQ scores in young children with FRAXA as well as in those with autism. Declines in IQ scores were steeper among children with FRAXA. Older children and adolescents with autism exhibit stable test-retest scores, whereas older children with FRAXA continue to show decreases. Comparable declines in adaptive behavior composite scores were observed in both groups, at all ages tested, and across all adaptive behavior domains.


European Journal of Human Genetics | 2003

X-linked spermine synthase gene (SMS) defect: the first polyamine deficiency syndrome

A. Lauren Cason; Yoshihiko Ikeguchi; Cindy Skinner; Tim Wood; Kenton R. Holden; Herbert A. Lubs; Francisco Venegas Martínez; Richard J. Simensen; Roger E. Stevenson; Anthony E. Pegg; Charles E. Schwartz

Polyamines (putrescine, spermidine, spermine) are ubiquitous, simple molecules that interact with a variety of other molecules in the cell, including nucleic acids, phospholipids and proteins. Various studies indicate that polyamines are essential for normal cell growth and differentiation. Furthermore, these molecules, especially spermine, have been shown to modulate ion channel activities of certain cells. Nonetheless, little is known about the specific cellular functions of these compounds, and extensive laboratory investigations have failed to identify a heritable condition in humans in which polyamine synthesis is perturbed. We report the first polyamine deficiency syndrome caused by a defect in spermine synthase (SMS). The defect results from a splice mutation, and is associated with the Snyder–Robinson syndrome (SRS, OMIM_309583), an X-linked mental retardation disorder. The affected males have mild-to-moderate mental retardation (MR), hypotonia, cerebellar circuitry dysfunction, facial asymmetry, thin habitus, osteoporosis, kyphoscoliosis, decreased activity of SMS, correspondingly low levels of intracellular spermine in lymphocytes and fibroblasts, and elevated spermidine/spermine ratios. The clinical features observed in SRS are consistent with cerebellar dysfunction and a defective functioning of red nucleus neurons, which, at least in rats, contain high levels of spermine. Additionally, the presence of MR reflects a role for spermine in cognitive function, possibly by spermines ability to function as an ‘intrinsic gateway’ molecule for inward rectifier K+ channels.


Journal of Medical Genetics | 2010

Phenotype and genotype in mucolipidoses II and III alpha/beta: a study of 61 probands

Sara S. Cathey; Jules G. Leroy; Tim Wood; Karisa Eaves; Richard J. Simensen; Mariko Kudo; Roger E. Stevenson; Michael J. Friez

Background Mucolipidoses II and III alpha/beta (ML II and ML III) are lysosomal disorders in which the essential mannose 6-phosphate recognition marker is not synthesised on to lysosomal hydrolases and other glycoproteins. The disorders are caused by mutations in GNPTAB, which encodes two of three subunits of the heterohexameric enzyme, N-acetylglucosamine-1-phosphotransferase. Objectives Clinical, biochemical and molecular findings in 61 probands (63 patients) are presented to provide a broad perspective of these mucolipidoses. Methods GNPTAB was sequenced in all probands and/or parents. The activity of several lysosomal enzymes was measured in plasma, and GlcNAc-1-phosphotransferase was assayed in leucocytes. Thirty-six patients were studied in detail, allowing extensive clinical data to be abstracted. Results ML II correlates with near-total absence of phosphotransferase activity resulting from homozygosity or compound heterozygosity for frameshift or nonsense mutations. Craniofacial and orthopaedic manifestations are evident at birth, skeletal findings become more obvious within the first year, and growth is severely impaired. Speech, ambulation and cognitive function are impaired. ML III retains a low level of phosphotransferase activity because of at least one missense or splice site mutation. The phenotype is milder, with minimal delays in milestones, the appearance of facial coarsening by early school age, and slowing of growth after the age of 4 years. Conclusions Fifty-one pathogenic changes in GNPTAB are presented, including 42 novel mutations. Ample clinical information improves criteria for delineation of ML II and ML III. Phenotype–genotype correlations suggested in more general terms in earlier reports on smaller groups of patients are specified and extended.


American Journal of Medical Genetics | 1996

Longitudinal study of cognitive abilities and adaptive behavior levels in fragile X males: A prospective multicenter analysis

Gene S. Fisch; Richard J. Simensen; Jack Tarleton; Maryse Chalifoux; Jeanette J. A. Holden; Nancy J. Carpenter; Patricia N. Howard-Peebles; Anne Maddalena

Retrospective longitudinal studies have noted declines in IQ scores in many but not all fra(X) (fragile X) males and females. We report on a prospective investigation of longitudinal changes in cognitive ability (IQ) and adaptive behavior (DQ) in 24 fra(X) males from four test sites. Individuals who were tested ranged in age from 3-15 years. To determine cognitive ability, all males were administered the Stanford-Binet test (4th Edition). To assess adaptive behavior, all males were evaluated using the Vineland Adaptive Behavior Scales. Mean interest interval was 2.3 years. Using identical DNA protocols, all subjects were identified as bearing the fra(X) mutation. Results showed declines in IQ scores in 18/24 (75%) males. Four males showed no change in scores. Declines in DQ scores were noted in 22/24 (92%) of those tested. DQ scores were higher than IQ scores in 20/24 (83%) subjects. From a descriptive cohort analysis, decreases in IQ scores appear to follow a well-defined, negatively decelerating function. Declines in DQ were steeper and more nearly linear. Declining scores are not indicative of regression of intellectual and/or social skills, but of a relative inability to keep pace with their age-normed cohort. We conclude that the fra(X) mutation affects cognitive abilities in a uniform, nonlinear manner comparable to outcomes observed in earlier retrospective studies. Adaptive behavior also declines, but in a more linear fashion.


American Journal of Human Genetics | 2006

Mutations in the Gene Encoding the Sigma 2 Subunit of the Adaptor Protein 1 Complex, AP1S2, Cause X-Linked Mental Retardation

Patrick Tarpey; Claire Stevens; Jon Teague; Sarah Edkins; Sarah O’Meara; Tim Avis; Syd Barthorpe; Gemma Buck; Adam Butler; Jennifer Cole; Ed Dicks; Kristian Gray; Kelly Halliday; Rachel Harrison; Katy Hills; Jonathon Hinton; David Jones; Andrew Menzies; Tatiana Mironenko; Janet Perry; Keiran Raine; David C. Richardson; Rebecca Shepherd; Alexandra Small; Calli Tofts; Jennifer Varian; Sofie West; Sara Widaa; Andy Yates; Rachael Catford

In a systematic sequencing screen of the coding exons of the X chromosome in 250 families with X-linked mental retardation (XLMR), we identified two nonsense mutations and one consensus splice-site mutation in the AP1S2 gene on Xp22 in three families. Affected individuals in these families showed mild-to-profound mental retardation. Other features included hypotonia early in life and delay in walking. AP1S2 encodes an adaptin protein that constitutes part of the adaptor protein complex found at the cytoplasmic face of coated vesicles located at the Golgi complex. The complex mediates the recruitment of clathrin to the vesicle membrane. Aberrant endocytic processing through disruption of adaptor protein complexes is likely to result from the AP1S2 mutations identified in the three XLMR-affected families, and such defects may plausibly cause abnormal synaptic development and function. AP1S2 is the first reported XLMR gene that encodes a protein directly involved in the assembly of endocytic vesicles.

Collaboration


Dive into the Richard J. Simensen's collaboration.

Top Co-Authors

Avatar

Roger E. Stevenson

Wellcome Trust Sanger Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge